Overview
Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 T cells and the investigators will determine the safety and therapeutic effects of these cells.
Eligibility
Inclusion Criteria:
CD19 positive leukemia and lymphoma，relapsed and/or refractory：
- survival>12 weeks;
- FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
- LVEF≥50%;
- Creatinine<2.5mg/dl;
- Bilirubin<2.5mg/dl;
- ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 x normal;
- At least 7 days after last chemotherapy;
- provide with informed consent.
Exclusion Criteria:
- Active clinically significant CNS dysfunction
- Pregnant or breast-feeding women.
- Uncontrolled active infection including hepatitis B or C.
- HIV positive.
- Use of systemic steroids within 72 hours.
- Allogeneic lymphocyte treatments within recent 6 months.
- Any uncontrolled active medical disorder.